Intuitive Biosciences

Established in 2012, Intuitive Biosciences, Inc. operates from Madison, Wisconsin, as a specialized life sciences company focused on supporting biomedical research. The firm provides high-throughput protein analysis tools and services, with a particular emphasis on monitoring the health of nonhuman primates (NHPs) for pharmaceutical companies, contract research organizations (CROs), and academic research institutions. The company's leadership includes Shawn Guse as President and CEO, Kimberly Luke as Vice President of Research and Development, and John Bart as Vice President of Operations.

Intuitive Biosciences has developed a comprehensive immunoassay platform known as the AIM (Arrayed Immuno-Multiplexing) system, which serves as a complete solution for serological screening and protein microarray analysis. The company's business model encompasses direct sales of its turnkey systems, which include analysis instruments and reporting software, as well as OEM solutions. A significant portion of its revenue is also generated from selling proprietary reagents and consumable assay kits, such as the Colony Surveillance Assay (CSA) kits. These kits are designed for the efficient screening of NHP blood samples for various infectious diseases, including tuberculosis and SARS-CoV-2. Furthermore, the company offers contract services, including assay development, production, and serology testing services, providing customized support for its clients' research needs.

The company's core technology includes its Colony Surveillance Assay (CSA) kits, which are available in various panels for screening up to 94 samples for multiple pathogens simultaneously. A key technological component is the SilverQuant colorimetric detection method, a stable and sensitive alternative to fluorescence-based detection for microarrays. This system allows for the visualization and quantification of biotinylated biomolecules, providing clear results for disease screening. In addition to product sales, Intuitive Biosciences provides testing services for viral and bacterial pathogens and consulting services for laboratory setup and training, reinforcing its position as a dedicated partner in NHP research. Since its first funding round in April 2013, the company has raised a total of $3.62 million over four rounds to support its operations and development.

Keywords: immunoassay platform, nonhuman primate health, serological screening, protein analysis tools, Colony Surveillance Assay, biomedical research support, veterinary diagnostics, infectious disease screening, multiplex immunoassays, SilverQuant detection, life sciences, contract research services, assay development, microarray analysis, animal health biomarkers, tuberculosis testing, SARS-CoV-2 screening, AIM system, diagnostic kits, laboratory consulting